Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

donor TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated natural killer cells

A preparation of donor-derived, haploidentical, cytokine-activated natural killer (NK) cells enriched with mononuclear cells from haploidentical donor that have been depleted of T-cell receptor (TCR) alpha and beta (TCRa/b+) as well as CD19-positive (CD19+) cells, that may potentially be used for immune reconstitution purposes. Upon administration, the donor TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated NK cells may enhance immune reconstitution. The depletion of alpha/beta T cells, which are implicated in the adaptive immune response that mediates graft-versus-host disease (GvHD), may promote rapid and sustained engraftment, immune reconstitution, and may prevent or reduce the development of GvHD. The depletion of CD19+ B cells may reduce the risk of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorders.
Synonym:allogeneic TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated NK cells
donor TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated NK cells
TCR alphabeta/CD19-depleted DEA-NK cells
TCR alphabeta/CD19-depleted donor enriched activated natural killer cells
Search NCI's Drug Dictionary